李娟LI, CHUAN謝煒翰HSIEH, WEI-HANWEI-HANHSIEH生物醫學科學學系碩士班2026-03-182030-08-1920252025-07-21https://handle.ncl.edu.tw/11296/ue4459https://scholars.csmu.edu.tw/handle/123456789/5996非小細胞肺癌(non-small cell lung cancer, NSCLC)仍是全球癌症相關死亡的主要原因。雖然表皮生長因子受體(epidermal growth factor receptor, EGFR)酪胺酸激酶抑制劑(tyrosine kinase inhibitor, TKI)的問世為NSCLC的治療帶來了重大進展,但抗藥性的出現依然嚴重限制其治療效果。第三代TKI Osimertinib雖是為克服T790M突變而開發,但腫瘤仍可能透過替代機制產生抗藥性,包括轉錄活化因子3(Signal Transducer and Activator of Transcription 3, STAT3)訊號活化、免疫逃脫與代謝重編程等,成為臨床上的重大挑戰。小孢子靈芝免疫調節蛋白(Ganoderma microsporum immunomodulatory protein, GMI)為一種源自小孢子靈芝的天然真菌蛋白,近年研究發現其具調控STAT3、自噬與免疫相關訊息傳導路徑的潛力。然而,GMI對EGFR-TKI抗藥性NSCLC的影響仍不明確。本研究以帶有EGFR突變並具Osimertinib抗藥性的H1975細胞模型為基礎,系統性探討GMI對細胞活性、訊息傳導、自噬、免疫相關標誌以及轉錄體變化的影響。我們的結果顯示,GMI能有效抑制H1975及其抗藥性細胞株的細胞活性,並與Osimertinib產生協同的細胞毒性作用。進一步分析發現,GMI可調控STAT的磷酸化,並調控CD47、MHC-I等免疫逃脫標誌。此外,RNA-Seq與後續驗證實驗指出,GMI能顯著改變STAT3與NSCLC相關基因(如IGFBP1與CCDC80)的轉錄與蛋白表現,並調節代謝標靶branched chain amino acid transaminase 1(BCAT1)及其下游代謝物alpha-ketoglutarate(α-KG),突顯其多方面的抗腫瘤機制。綜合以上,GMI可透過多方傳導路徑干擾Osimertinib抗藥性NSCLC細胞的生存機制,具有作為EGFR-TKI輔助治療策略的潛力。Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Although the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has brought significant advances in the treatment of NSCLC, the emergence of drug resistance continues to severely limit their therapeutic efficacy. The third-generation TKI, Osimertinib, was developed to overcome the T790M mutation; however, tumors can still acquire resistance through alternative mechanisms, including activation of signal transducer and activator of transcription 3 (STAT3) signaling, immune evasion, and metabolic reprogramming, posing a major clinical challenge. Ganoderma microsporum immunomodulatory protein (GMI), a natural fungal protein derived from Ganoderma microsporum, has recently been shown to have the potential to regulate STAT3, autophagy, and immune-related signaling pathways. Nevertheless, the impact of GMI on EGFR-TKI–resistant NSCLC remains unclear.In this study, we employed the EGFR-mutant and Osimertinib-resistant H1975 cell model to systematically investigate the effects of GMI on cell viability, signaling pathways, autophagy, immune-related markers, and transcriptomic alterations. Our results demonstrated that GMI effectively inhibited the viability of both H1975 cells and their resistant subclones, and exhibited synergistic cytotoxicity when combined with Osimertinib. Further analyses revealed that GMI modulates STAT phosphorylation and regulates immune evasion markers such as CD47 and MHC-I. Moreover, RNA-Seq and subsequent validation experiments indicated that GMI significantly altered the transcription and protein expression of STAT3- and NSCLC-associated genes (such as IGFBP1 and CCDC80), and regulated the metabolic target branched chain amino acid transaminase 1 (BCAT1) and its downstream metabolite alpha-ketoglutarate (α-KG), highlighting its multifaceted anti-tumor mechanisms.Taken together, GMI interferes with the survival machinery of Osimertinib-resistant NSCLC cells through multiple signaling pathways and holds promise as a potential adjunct therapeutic strategy to EGFR-TKIs.非小細胞肺癌Osimertinib抗藥性小孢子靈芝免疫調節蛋白STAT3免疫逃脫Non-small cell lung cancerOsimertinib resistanceGanoderma microsporum immunomodulatory proteinimmune evasion小孢子靈芝免疫調節蛋白抑制STAT3並改善Osimertinib抗藥性之非小細胞肺癌細胞研究thesis